Dr Andrew Rut, CEO of SaaS provider My Meds & Me discusses why AI can revolutionise drug development and healthcare but caution over data is critical for success.
Artificial intelligence (AI) has the potential to transform healthcare and automate key steps in the drug research and development (R&D) process. With increasing and increasingly diverse data sources researchers are utilising AI to process and analyse data, with the aim of better understanding disease, drug targets and responses to therapies. AI’s potential to revolutionise healthcare is reflected not only in its adoption and the investment by big pharma but also by the healthcare divisions of tech giants such as Google and Microsoft. Yet we are just at the start of discovering AI’s power and possibilities and the smart companies will be the ones who learn fast from mistakes made along the way and understand that AI must always be used intelligently to ensure it works to improve the quality of patients’ lives in meaningful ways.